The matrix protein 2 (M 2 ) blocker, Amantadin, is approved by FDA to treat and control of influenza A virus infections in children and adults. Recently, some substitutions at amino acid positions are causing the emergence of anti viral drug-resistant strains of influenza virus.
Amantadin resistant variants of influenza
62.5% of positive cases were 0-3 years, 10% of them were 4-6 years, and 27.5% were 7-10 years. The result shows 70% were male. 50% of positive cases affected sporadic. Clinical symptoms in these positive cases were as follows: Sudden onset 51%, fever 69.4%, headache 21.8%, coryza 82.5%, weakness 54.8%, pharingitis 41.1%, bronchodyspenia 4%, cough 11.3%, agitation 58%, sputum 59.7%, and muscle pain 8%, gastrointestinal problem, 23.4%, otitis 13%. 97.5% of these forty cases did not received influenza vaccine and 40% received antibiotic.
Our data show that Amantadin resistant A/H 3 N 2 is caused by a single amino acid mutation that makes a Ser 31 Asp substitution in M 2 protein. Since these children might not used Amantadin, the drug resistance determined in this project is not related to direct usage of Amantadin by the patient. Continued surveillance is required to elucidate full Amantadin-resistant pattern of influenza virus in Iranian children, especially in the recent pandemics.
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